Angiogenesis modulates the tumour immune response.
Outgrowth of solid tumors and metastases is dependent on the process of angiogenesis. Tumors escape from the formation of an effective infiltrate by downregulation of endothelial adhesion molecules. This downregulation of adhesion receptors is governed by the exposure to angiogenic factors. In recent years proof for this has been provided by demonstrating that freshly isolated tumor endothelial cells exhibit a decreased expression of ICAM-1 and -2 as compared to endothelial cells in normal tissue. In addition, adhesion molecules are downregulated on normal tissue endothelial cells when cultured with angiogenesis stimulators such as basic fibroblast growth factor and vascular endothelial cell growth factor, while under these conditions endothelial cells become less responsive to cytokines such as tumor necrosis factor-alpha with respect to the upregulation of endothelial adhesion molecules. Very recently it has been demonstrated that this harmful endothelial cell anergy can be counteracted by inhibitors of angiogenesis.
D000818:Animals; D007167:Immunotherapy / Q000379:methods; D007962:Leukocytes / Q000276:immunology; D051379:Mice; D009369:Neoplasms / Q000098:blood supply* / Q000276:immunology / Q000628:therapy; D009389:Neovascularization, Pathologic / Q000276:immunology*; D051381:Rats